Full FDA Approval for Camptosar
ROCKVILLE, Md-The FDA has granted full approval to Pharmacia & Upjohn’s Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
ROCKVILLE, MdThe FDA has granted full approval to Pharmacia & Upjohns Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.
